■casirivimab-imdevimab治疗2019年冠状病毒病的优缺点尚不清楚。我们对相关文献进行了系统评价和荟萃分析,以确定casirivimab-imdevimab在COVID-19患者中的治疗效果和潜在副作用。
■从数据库开始到2月28日,2023年。评估的主要结果是28天的死亡率,28天内当前临床症状的进展,病毒载量,出院,和任何不良事件。此外,我们对比了casirivimab-imdevimab治疗与安慰剂或标准治疗的效果.本系统评价和荟萃分析的方案注册记录在PROSPERO数据库(CRD42023412835)中。
■共纳入8项研究,包括19,819名患者,并使用Cochrane偏差风险工具对其偏差风险进行了定性评估。Casirivimab-imdevimab有效降低了死亡率(OR=0.62;95%CI为0.40-0.98;p=0.04;I2=30%),并减少了临床症状的进展(OR=0.86;95%CI为0.79-0.93;p=0.0003;I2=57%)。Casirivimab-imdevimab还改善了病毒载量清除和出院。此外,试验结果表明,使用casirivimab-imdevimab发生不良事件的可能性略有下降.
■我们的研究表明,casirivimab-imdevimab可能是一种有价值的,安全,和有效的抗SARS-CoV-2方案。
UNASSIGNED: The advantages and disadvantages of
casirivimab-imdevimab for coronavirus disease 2019 are not well understood. We conducted a systematic review and meta-analysis of relevant literature to determine the therapeutic effectiveness and potential side effects of casirivimab-imdevimab in COVID-19 patients.
UNASSIGNED: Databases were searched from the time of their commencement until February 28th, 2023. The primary results evaluated were the death rate at 28 days, progression of current clinical symptoms within 28 days, viral load, discharge from hospital, and any adverse events. Also, we contrasted the effects of the
casirivimab-imdevimab treatment with placebo or standard of care. The protocol registration for this systematic review and meta-analysis was recorded in the PROSPERO database (CRD42023412835).
UNASSIGNED: A total of eight studies were included, comprising 19,819 patients, and conducted a qualitative assessment of their risk of bias using the Cochrane risk of bias tool.
Casirivimab-imdevimab effectively reduced the mortality rate (OR = 0.62; 95 % CI of 0.40-0.98; p = 0.04; I2 = 30 %) and reduced the progression of clinical symptoms (OR = 0.86; 95 % CI of 0.79-0.93; p = 0.0003; I2 = 57 %).
Casirivimab-imdevimab also improved viral load clearance and hospital discharge. Additionally, the trials\' findings demonstrated a slight decrease in the likelihood of adverse events occurring with the use of casirivimab-imdevimab.
UNASSIGNED: Our research suggests that
casirivimab-imdevimab may be a valuable, safe, and effective anti-SARS-CoV-2 regimen.